The potentially decrease medical remedy charge of ceftriaxone must be well balanced towards the possible benefits of parenteral therapy (see Scientific Research).In primates, no embryotoxicity or teratogenicity was shown in a dose close to three situations the human dose.If this SPL includes inactivated NDCs listed with the FDA initiated compliance